Evidence map›Paper›PMID 31261785›Full record

ReviewJournal of clinical medicine2019

Current Therapeutic Options in the Treatment of Rheumatoid Arthritis.

Birgit M Köhler, Janine Günther, Dorothee Kaudewitz, Hanns-Martin Lorenz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Quantum Health AcceleratorBrain sciences · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Birgit M KöhlerInternal Medicine 5, Division of Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. birgit.koehler@med.uni-heidelberg.de.
Janine GüntherInternal Medicine 5, Division of Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. janine.guenther@med.uni-heidelberg.de.
Dorothee KaudewitzInternal Medicine 5, Division of Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. dorothee.kaudewitz@med.uni-heidelberg.de.
Hanns-Martin LorenzInternal Medicine 5, Division of Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Hannes.Lorenz@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of the joints. Untreated RA leads to a destruction of joints through the erosion of cartilage and bone. The loss of physical function is the consequence. Early treatment is important to control disease activity and to prevent joint destruction. Nowadays, different classes of drugs with different modes of action are available to control the inflammation and to achieve remission. In this review, we want to discuss differences and similarities of these different drugs.

Indexed as

DMARDMTXRheumatoid ArthritistherapyTumor Necrosis Factor-Alpha Inhibitors

Identifiers

PMID31261785
PMCPMC6678427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.